repeat SPBx (median 28 cores; range: 26-31) for persistent suspicious of PCa. The indications for biopsy were (7): abnormal digital rectal examination (DRE), persistent elevated or increasing PSA values, PSA > 10 ng/mL, PSA values between 4.1-10 with free/total PSA < 25%. Prostate biopsy was performed transperineally (8) using a tru-cut 18 gauge needle (Bard; Covington, GA), a GE Logiq 500 PRO ecograph (General Electric; Milwaukee, WI) supplied with a biplanar transrectal probe (5-6.5 MHz). The SPBx included at least 12 cores in the posterior zone of each lobe (apex, middle zone and base of the gland) beginning parasagittally to reach the outer edges of the gland (lateral margins) plus 2-3 cores in the transition and anterior zone. The procedure was performed under sedation and antibiotic prophylaxis, respectively. Among clinical complications incidence of ED was evaluated only in men with benign histology (normal parenchyma), on the contrary patients with cancer, ASAP or HGPIN were not included to eliminate anxiety from the hypothetical cause of ED. All patients were prospectively evaluated 
INTRODUCTION
Prostate cancer (PCa) is the most frequent tumor diagnosed in elder men with about 1 million biopsies for year performed in the United States (1) . In the last decade a greater rate of prostate biopsy side effects has been reported and serious complications incidence requiring hospital admission ranges from 1.2% (2) to 2.5% (1) secondary, in the most of the cases, to urinary tract infection (UTI), fever or sepsis (in case of transrectal biopsy). Among minor complications erectile dysfunction (ED) has been reported in a little percentage of patients and it has been ascribed to anxiety (3) , local anesthesia and/or number of needle cores (4, 5) inducing a clinical impact on patient well-being and quality of life (6). In our study ED incidence following repeat transperineal saturation prostate biopsy (SPBx) was prospectively evaluated.
MATERIALS AND METHODS
From January 2011 to June 2012 295 patients of ages between 56 and 71 years (median 63 years) underwent ORIGINAL PAPER Erectile function after repeat saturation prostate biopsy: Our experience in 100 patients Summary repeat SPBx (median 28 cores; range: 26-31) for persistent suspicious of PCa. The indications for biopsy were (7): abnormal digital rectal examination (DRE), persistent elevated or increasing PSA values, PSA > 10 ng/mL, PSA values between 4.1-10 with free/total PSA < 25%. Prostate biopsy was performed transperineally (8) using a tru-cut 18 gauge needle (Bard; Covington, GA), a GE Logiq 500 PRO ecograph (General Electric; Milwaukee, WI) supplied with a biplanar transrectal probe (5-6.5 MHz). The SPBx included at least 12 cores in the posterior zone of each lobe (apex, middle zone and base of the gland) beginning parasagittally to reach the outer edges of the gland (lateral margins) plus 2-3 cores in the transition and anterior zone. The procedure was performed under sedation and antibiotic prophylaxis, respectively. Among clinical complications incidence of ED was evaluated only in men with benign histology (normal parenchyma), on the contrary patients with cancer, ASAP or HGPIN were not included to eliminate anxiety from the hypothetical cause of ED. All patients were prospectively evaluated with the 5-item version of the International Index of Erectile Function (IIEF-5) (9) before and 1, 3 and 6 months from SPBx. None of the patients used 5-phosphodiesterase inhibitors or prostaglandins to improve sexual activity. For statistical analysis the t Student' -test was used; a p value < 0.05 was considered statistically significant.
RESULTS
Histological specimen showed a PCa in 90/295 (30.5%) cases, an HGPIN in 4 (1.3%), an ASAP 1 (0.4%) and a normal parenchyma in 200 (67.8%), respectively; 100/200 (50%) men with a referred normal sexual activity characterized by a median baseline IIEF-5 score equal to 18.3 (range: 16-25) completed the study. Clinical (comorbidities, drug therapy) and laboratory data collected before SPBx are reported in Table 1 . Among clinical complications none of the patients needed hospital admission and 10 (10%) underwent emergency clinic visit within 2 day (median; range: 1-3 days) from SPBx in 7 cases (7%) for acute urinary retention, in 2 (2%) for gross hematuria and in 1 (1%) for urinary tract infection; moreover, hemospermia was the most frequent side effect recorded in 36 (36%) and 9 (9%) patients 3 and 6 months from the procedure, respectively. A significantly difference between IEEF-5 score at baseline (18.3) and 1 (17.8), 3 (18) and 6 (18.1) months from SPBx was not found (p > 0.05) ( Table 2 ); in detail, after 1 month 5 (5%) patients with a pre-biopsy normal sexual activity (IIEF > 22) referred a mild DE that disappeared at 3 and 6 months evaluation (Table 2) .
DISCUSSION
A minimal risk of temporary ED following prostate biopsy has been correlated with the increasing number of needle cores, use of periprostatic nerve block, disease involving neurovascular bundles, anxiety and diagnosis of PCa. Although Tuncel et al. (10) reported a male sexual dysfunction combined with negative effect on female sexual function exceeding six months from biopsy, most of the papers (5,10) agree that prostate biopsies could have a significantly impact on short-term (30 days) erectile function that disappears at medium-term (3-6 months). Glaser et al (3) in a systematic review reported that prostate biopsy was associated with short-term exacerbation of urinary symptoms score, anxiety and ED without a distinct relationship to the periprostatic nerve block or the number of cores biopsied. Zisman et al. (4) In our series, to our knowledge the first that evaluated patients submitted to repeat transperineal SPBx under sedation, ED incidence did not significantly increased 1, 3 and 6 months from biopsy; only 5/100 (5%) men with a pre-biopsy normal sexual activity (IEEF-5 > 22) referred at first month evaluation a mild ED (IEEF-5 score between 17 and 21) that disappeared 3-6 months later.
Regarding our results some considerations should be done. Firstly, the true sexual activity of the couple administering a sexual questionnaire to the partners was not investigated. Secondly, we don't know if the transperineal biopsy approach and/or the absence of local anesthesia had a clinical impact on our results. Finally, in the absence a of control group we don't know if the onset of DE one month from SPBx (5% of the cases) was really given by prostate biopsy.
In conclusion, repeat transperineal SPBx under sedation did not significantly worsened erectile function; the minimal risk of temporary post-biopsy ED could be previously discussed (not emphasised) with potent patients.
